Published in Magn Reson Med on April 01, 2008
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev (2010) 1.82
Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br J Radiol (2010) 1.36
Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl (2010) 1.19
Recent trends in antibody-based oncologic imaging. Cancer Lett (2011) 1.17
HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One (2011) 1.09
Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models. Sci Rep (2016) 1.09
MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc (2010) 1.08
Molecular imaging and targeted therapies. Biochem Pharmacol (2010) 1.05
A new approach in the preparation of dendrimer-based bifunctional diethylenetriaminepentaacetic acid MR contrast agent derivatives. Bioconjug Chem (2009) 0.96
Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem (2013) 0.88
Fluorescence imaging agents in cancerology. Radiol Oncol (2010) 0.87
Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma. Cancer Res (2011) 0.85
Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol (2010) 0.82
Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.79
Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. Int J Nanomedicine (2013) 0.79
Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth (2011) 0.78
GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI. Sci Rep (2015) 0.77
Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential? Macromolecules (2012) 0.77
Molecular platform for design and synthesis of targeted dual-modality imaging probes. Bioconjug Chem (2015) 0.76
Novel DNA Polymer for Amplification Pretargeting. ACS Med Chem Lett (2015) 0.75
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem (1981) 38.93
The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem (1979) 9.06
Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today (2006) 4.35
Technical aspects of immunohistochemistry. Vet Pathol (2005) 3.51
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol (2003) 2.47
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs (1999) 1.67
Effects of glomerular filtration rate on Ficoll sieving coefficients (theta) in rats. Kidney Int (2006) 1.67
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Plasma proteins modify the endothelial cell glycocalyx of frog mesenteric microvessels. J Physiol (1992) 1.50
Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging (2003) 1.49
3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med (2001) 1.49
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 1.49
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res (1991) 1.38
Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res (1996) 1.17
Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med (2001) 1.17
Characteristics of a new MRI contrast agent prepared from polypropyleneimine dendrimers, generation 2. Invest Radiol (2003) 1.14
Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magn Reson Med (2005) 1.14
Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med (2006) 1.08
Functional magnetic resonance imaging of the kidney using macromolecular contrast agents. Abdom Imaging (2006) 0.95
Renal glomerular permselectivity and vascular endothelium. Biomed Pharmacother (2005) 0.87
The biodistribution of NC100668 and the effect of excess NC100668 on the biodistribution and kidney retention of (99m)Tc-NC100668 in the rat. Nucl Med Biol (2007) 0.79
Failure of layer-by-layer multilayers composed of neutravidin-biotin-labeled antibody for sandwich fluoroimmunosensing. Biosens Bioelectron (2007) 0.79
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med (2013) 2.74
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res (2005) 2.32
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Self-assembled three dimensional radio frequency (RF) shielded containers for cell encapsulation. Biomed Microdevices (2005) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res (2003) 1.26
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid. J Magn Reson (2013) 1.23
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol (2004) 1.17
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging (2005) 1.08
Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt (2012) 1.08
Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.06
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed (2010) 1.03
Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia (2007) 1.02
Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods. Proc IEEE Inst Electr Electron Eng (2005) 1.02
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano (2010) 1.01
Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res (2006) 1.00
Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia (2008) 1.00
Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med (2007) 1.00
Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol (2004) 1.00
Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol (2007) 0.99
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed (2012) 0.99
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol (2010) 0.98
Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia (2006) 0.97
Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med (2002) 0.96
Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther (2007) 0.95
Multimodal image-guided enzyme/prodrug cancer therapy. J Am Chem Soc (2006) 0.95
Proline oxidase promotes tumor cell survival in hypoxic tumor microenvironments. Cancer Res (2012) 0.94
Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng (2012) 0.94
Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia (2009) 0.94
Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2. Cancer Biol Ther (2009) 0.94
Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol Imaging (2008) 0.94
Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging (2004) 0.93
Localized hypoxia results in spatially heterogeneous metabolic signatures in breast tumor models. Neoplasia (2012) 0.93
Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat (2004) 0.92
Applications of molecular MRI and optical imaging in cancer. Future Med Chem (2010) 0.92
Monitoring of release of cargo from nanocarriers by MRI/MR spectroscopy (MRS): significance of T2/T2* effect of iron particles. Magn Reson Med (2009) 0.92
Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism. Neoplasia (2007) 0.92
Cell viability and noninvasive in vivo MRI tracking of 3D cell encapsulating self-assembled microcontainers. Cell Transplant (2007) 0.91
MR molecular imaging of tumor vasculature and vascular targets. Adv Genet (2010) 0.91
Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft. Cancer Res (2009) 0.90
Magnetic resonance imaging and spectroscopy of transgenic models of cancer. NMR Biomed (2007) 0.90
COX-2 in cancer: Gordian knot or Achilles heel? Front Pharmacol (2013) 0.89
Synthesis of 6'-O-lissamine-rhodamine B-glucosamine as a novel probe for fluorescence imaging of lysosomes in breast tumors. Bioconjug Chem (2005) 0.89
Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content. Int J Hyperthermia (2014) 0.88
Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn Reson Med (2006) 0.88
Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. Cancer Biol Ther (2007) 0.88
Cancer cachexia, recent advances, and future directions. Cancer J (2015) 0.87
The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Neoplasia (2008) 0.87
Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique. Biomaterials (2010) 0.86
CAM-CM: a signal deconvolution tool for in vivo dynamic contrast-enhanced imaging of complex tissues. Bioinformatics (2011) 0.86